Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 3/1/2000


1.		Phase II Pilot Study of Vaccination with Breast Cancer Mucin Peptide and Keyhole Limpet Hemocyanin plus the Immunologic Adjuvant QS21 for High-Risk Breast Cancer after Definitive Therapy: Stage I/II/IIIA with Rising Tumor Markers and Stage IIIB/IV (Summary Last Modified 03/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified				NCI				MSKCC-94130 NCI-H95-0628

Last Modified: 5/1/2002 First Published: 12/1/1999


2.		Phase II Study of Vaccination With Glycosylated MUC-1 Antigen With Keyhole Limpet Hemocyanin Conjugate Plus Immunological Adjuvant QS21 in Patients With High Risk Breast Cancer (Summary Last Modified 05/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MSKCC-99023 NCI-H99-0043, NCT00004156

Last Modified: 5/1/1997


3.		Phase I Study of Vaccination with MUC-1-KLH Conjugate with the Immunologic Adjuvant QS21 for Recurrent Prostate Cancer (Summary Last Modified 05/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Other				MSKCC-96023 NCI-V96-0877

Last Modified: 5/1/2002 First Published: 5/1/2000


4.		Phase I Study of Vaccination With Glycosylated MUC-1 Antigen With Keyhole Limpet Hemocyanin Conjugate Plus Immunological Adjuvant QS21 in Patients With Prostate Cancer (Summary Last Modified 05/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				MSKCC-99040 NCI-G00-1773, NCT00005632

Last Modified: 10/1/2000 First Published: 7/1/2000


5.		Phase I Study of Glycosylated MUC-1-KLH Vaccine Plus Adjuvant QS21 in Patients With Ovarian, Fallopian Tube, or Peritoneal Epithelial Cancer (Summary Last Modified 10/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				MSKCC-99121 NCI-H00-0060, NCT00006041

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute